Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CADL |
---|---|---|
09:32 ET | 5054 | 6.26 |
09:36 ET | 499 | 6.275 |
09:41 ET | 13760 | 6.38 |
09:43 ET | 3757 | 6.37 |
09:45 ET | 1500 | 6.375 |
09:48 ET | 1600 | 6.33 |
09:52 ET | 12187 | 6.35 |
09:54 ET | 299 | 6.33 |
09:57 ET | 616 | 6.35 |
09:59 ET | 12804 | 6.34 |
10:01 ET | 650 | 6.33 |
10:03 ET | 100 | 6.34 |
10:10 ET | 231 | 6.32 |
10:12 ET | 300 | 6.3 |
10:19 ET | 9952 | 6.29 |
10:24 ET | 150 | 6.3 |
10:30 ET | 1716 | 6.365 |
10:32 ET | 100 | 6.35 |
10:35 ET | 466 | 6.335 |
10:39 ET | 125 | 6.34 |
10:42 ET | 1600 | 6.35 |
10:44 ET | 1292 | 6.36 |
10:50 ET | 200 | 6.35 |
10:51 ET | 12150 | 6.295 |
11:02 ET | 1500 | 6.27 |
11:06 ET | 300 | 6.2827 |
11:08 ET | 300 | 6.26 |
11:11 ET | 600 | 6.26 |
11:13 ET | 960 | 6.262 |
11:18 ET | 300 | 6.29 |
11:22 ET | 608 | 6.2938 |
11:24 ET | 100 | 6.29 |
11:26 ET | 326 | 6.2625 |
11:27 ET | 320 | 6.2977 |
11:29 ET | 700 | 6.31 |
11:38 ET | 100 | 6.29 |
11:42 ET | 200 | 6.29 |
11:44 ET | 614 | 6.26 |
11:45 ET | 300 | 6.26 |
11:47 ET | 100 | 6.29 |
11:49 ET | 300 | 6.29 |
11:56 ET | 591 | 6.2601 |
12:00 ET | 100 | 6.285 |
12:05 ET | 1523 | 6.29 |
12:07 ET | 200 | 6.26 |
12:09 ET | 700 | 6.26 |
12:12 ET | 1300 | 6.25 |
12:16 ET | 1100 | 6.24 |
12:18 ET | 700 | 6.24 |
12:21 ET | 700 | 6.21 |
12:30 ET | 100 | 6.21 |
12:36 ET | 600 | 6.2299 |
12:39 ET | 1600 | 6.215 |
12:41 ET | 787 | 6.21 |
12:45 ET | 200 | 6.2 |
12:48 ET | 13967 | 6.15 |
12:50 ET | 1377 | 6.1275 |
12:52 ET | 1306 | 6.17 |
12:56 ET | 12155 | 6.105 |
12:57 ET | 100 | 6.08 |
12:59 ET | 14505 | 6.08 |
01:03 ET | 100 | 6.065 |
01:06 ET | 600 | 6.05 |
01:08 ET | 422 | 6.06 |
01:10 ET | 379 | 6.075 |
01:14 ET | 200 | 6.05 |
01:19 ET | 1829 | 6.05 |
01:21 ET | 1200 | 6.05 |
01:24 ET | 210 | 6.05 |
01:26 ET | 1200 | 6.06 |
01:28 ET | 1300 | 6.04 |
01:33 ET | 2297 | 6.02 |
01:37 ET | 200 | 6.02 |
01:42 ET | 200 | 6.018 |
01:44 ET | 2582 | 6.015 |
01:46 ET | 1000 | 6 |
01:48 ET | 330 | 6.01 |
01:50 ET | 300 | 6.0356 |
02:11 ET | 6969 | 5.92 |
02:13 ET | 60036 | 5.85 |
02:15 ET | 5828 | 5.86 |
02:18 ET | 1201 | 5.87 |
02:20 ET | 14350 | 5.87 |
02:22 ET | 1700 | 5.89 |
02:24 ET | 100 | 5.86 |
02:26 ET | 21926 | 5.815 |
02:27 ET | 750 | 5.83 |
02:29 ET | 1050 | 5.84 |
02:31 ET | 11817 | 5.78 |
02:33 ET | 5598 | 5.8 |
02:38 ET | 100 | 5.81 |
02:40 ET | 3400 | 5.84 |
02:42 ET | 1000 | 5.8513 |
02:44 ET | 348 | 5.848 |
02:45 ET | 500 | 5.85 |
02:47 ET | 100 | 5.8496 |
02:49 ET | 23997 | 5.85 |
02:56 ET | 1200 | 5.81 |
03:00 ET | 6443 | 5.865 |
03:02 ET | 200 | 5.8771 |
03:03 ET | 200 | 5.8771 |
03:05 ET | 3350 | 5.88 |
03:07 ET | 9012 | 5.825 |
03:12 ET | 3100 | 5.83 |
03:14 ET | 4231 | 5.805 |
03:16 ET | 138 | 5.8001 |
03:20 ET | 400 | 5.82 |
03:21 ET | 892 | 5.81 |
03:23 ET | 9132 | 5.78 |
03:25 ET | 100 | 5.785 |
03:27 ET | 200 | 5.77 |
03:30 ET | 900 | 5.7999 |
03:32 ET | 5070 | 5.82 |
03:34 ET | 1474 | 5.8 |
03:36 ET | 3050 | 5.77 |
03:38 ET | 200 | 5.785 |
03:39 ET | 200 | 5.7785 |
03:41 ET | 3600 | 5.79 |
03:43 ET | 300 | 5.7892 |
03:45 ET | 1400 | 5.81 |
03:48 ET | 200 | 5.8 |
03:50 ET | 1924 | 5.79 |
03:52 ET | 500 | 5.83 |
03:54 ET | 818 | 5.83 |
03:56 ET | 2860 | 5.84 |
03:57 ET | 7826 | 5.805 |
03:59 ET | 7401 | 5.82 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Candel Therapeutics Inc | 173.2M | -4.5x | --- |
Trevi Therapeutics Inc | 181.7M | -7.6x | --- |
Acrivon Therapeutics Inc | 218.3M | -2.5x | --- |
Rani Therapeutics Holdings Inc | 188.6M | -2.9x | --- |
Aldeyra Therapeutics Inc | 189.5M | -6.3x | --- |
Immutep Ltd | 288.3M | -7.4x | --- |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $173.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.